Therapeutic Plasma Exchange and Longevity: A Review of Recent Evidence

Aging is increasingly understood not merely as a cell-autonomous process but as one driven by systemic alterations in circulating factors that govern tissue maintenance and regeneration.[1] The concept that blood-borne components actively dictate the tempo of aging — shaping immune remodeling, metabolic homeostasis, and interorgan communication — has catalyzed interest in therapeutic plasma exchange (TPE) as a potential longevity intervention. Originally developed for autoimmune and hematologic conditions, TPE is now being investigated for its capacity to remove pro-aging circulating factors, reduce chronic inflammation, and restore a more youthful proteomic environment.[2][3]

In this article we review the most recent evidence on TPE and biological aging, including landmark clinical trials, mechanistic insights, and critical perspectives on clinical translation. For related coverage, see our companion articles on TPE, biological aging, and Alzheimer’s disease and expanding uses of TPE for longevity, PFAS, and microplastics.

Preclinical Foundations: From Parabiosis to Plasma Dilution

The scientific rationale for TPE in aging originates from heterochronic parabiosis experiments, in which surgically conjoined young and old mice share a circulatory system. These studies demonstrated that exposure to a youthful systemic milieu rejuvenates stem cells, reduces cellular senescence, and restores tissue function across multiple organs — including the brain, muscle, liver, and heart.[4][5][6] Critically, single-cell transcriptomic atlases have shown that hematopoietic stem and progenitor cells are among the most responsive cell types to young blood exposure, from which a cascade of immune and regenerative restoration emanates.[4]

A pivotal conceptual advance came from the demonstration that young blood itself is not necessary for rejuvenation. Mehdipour et al. showed that a single “neutral blood exchange” (NBE) — replacing half of old mouse plasma with saline-albumin — was sufficient to enhance muscle repair, reduce liver adiposity and fibrosis, increase hippocampal neurogenesis, and improve cognition in aged mice.[7][8] Proteomic analysis of both NBE in mice and TPE in humans revealed a molecular resetting of the systemic signaling milieu, with elevated levels of proteins that coordinate tissue maintenance, repair, and immune responses.[7] These findings shifted the paradigm from “young blood contains rejuvenating factors” to “old blood contains pro-aging factors whose dilution is sufficient for rejuvenation.” Meaning, removing old plasma is key to the improvement and to optimizing human systems. TPE has thus been called the “oil change of the human body.”

The First Randomized Placebo-Controlled Trial: Multi-Omics Evidence for Biological Age Rejuvenation

The most significant recent clinical advance is the first randomized, placebo-controlled, multi-omics trial of TPE for biological aging, published by Fuentealba, Kiprov, and colleagues in Aging Cell (2025).[9] This study enrolled 42 healthy adults over age 50 and randomized them to bi-weekly TPE with or without intravenous immunoglobulin (IVIG), monthly TPE, or placebo. The primary objectives were long-term TPE safety and changes in biological clocks.

Key findings included:

• Safety: Long-term TPE was found to be safe, with only two adverse events requiring discontinuation and one related to IVIG.[9] This is unsurprising, as TPE has decades of data demonstrating its efficacy and safety.
• Epigenetic rejuvenation: TPE significantly improved biological age markers, with 15 epigenetic clocks showing rejuvenation compared to placebo (FDR < 0.05).[9]
• Optimal regimen: Bi-weekly TPE combined with IVIG (TPE-IVIG) proved most effective, inducing coordinated cellular and molecular responses, reversing age-related immune decline, and modulating proteins linked to chronic inflammation.[9]
• Predictive biomarkers: Integrative analysis identified baseline biomarkers predictive of positive outcomes, suggesting TPE-IVIG is particularly beneficial for individuals with poorer initial health status.[9]
• Multi-omics changes: Longitudinal profiling across the epigenome, proteome, metabolome, glycome, immune cytokines, iAge, and immune cell composition demonstrated broad molecular rejuvenation.[9]

This trial represents the first multi-omics study to examine various TPE modalities and demonstrate biological age rejuvenation, along with the molecular features associated with that rejuvenation.

Ready to start your TPE journey? Request a consultation.

Conflicting Evidence: Plasmapheresis Without Replacement May Accelerate Aging

In contrast to the above findings, a 2025 cross-over clinical trial by Borsky et al. in Scientific Reports examined plasmapheresis without volume replacement with young plasma or albumin in healthy blood donors.[10] Participants underwent either 4 or 8 plasmapheresis sessions over 18 weeks.

While the procedure altered serum minerals, decreased lipids (total cholesterol, non-HDL, triglycerides, apolipoprotein A), and reduced total proteins and albumin, no significant epigenetic rejuvenation was observed.[10] Instead, plasmapheresis was associated with increases in DNAmGrimAge, the Hannum clock, and the Dunedin Pace of Aging — suggesting it may actually accelerate epigenetic aging.[10]

This discrepancy highlights a critical point: the replacement fluid matters. TPE with albumin or IVIG replacement appears to yield different biological outcomes than simple plasmapheresis without replacement. The protocol — including frequency, volume, and replacement strategy — is likely a key determinant of whether the procedure rejuvenates or harms. This is why expert-led, physician-supervised care is paramount to getting the benefit you are looking for.

Mechanistic Framework: SASP, Inflammaging, and Immune Remodeling

A 2025 review by Akgun in Ageing Research Reviews provides a comprehensive mechanistic framework for understanding how TPE may counteract aging.[2] Aging is driven by cellular senescence and chronic inflammation, largely mediated by the senescence-associated secretory phenotype (SASP). SASP factors promote “inflammaging,” impair tissue homeostasis, and contribute to age-related diseases including cardiovascular disease, neurodegeneration, and cancer.[2]

TPE is proposed to act through several mechanisms:

1. Removal of pro-aging factors: Inflammatory cytokines, metabolic waste products, and senescence-associated proteins are physically removed from circulation.[2]
2. Replenishment of rejuvenating factors: Replacement with albumin or donor plasma restores factors that support tissue maintenance.[2][7]
3. Immune remodeling: TPE reverses age-related immune decline, modulating the balance between pro-inflammatory and anti-inflammatory immune cell populations.[9]
4. Signaling pathway normalization: Circulatory regulators of the JAK-STAT, MAPK, TGF-β, NF-κB, and Toll-like receptor signaling pathways become more youthfully balanced, with TLR4 identified as a nodal point of molecular rejuvenation.[11]

The review also introduces the concept of selective apheresis — targeting specific SASP components rather than exchanging entire plasma volumes — as a potential next-generation precision approach.[2]

Blood as a Central Regulatory Axis of Aging

A 2026 review synthesizes the broader evidence positioning blood as both a mirror and modulator of organismal aging.[1] Multi-omics advances in plasma proteomics, metabolomics, and single-cell immunomics have revealed that circulating proteins and metabolites reflect not only chronological and biological age but also organ-specific aging trajectories, serving as robust predictors of health span, longevity, and disease risk.[1]

The review highlights that specific blood fractions — including small extracellular vesicles, plasma proteins, and metabolites — can restore mitochondrial function, suppress inflammation, and extend lifespan in animal models. Conversely, reducing pro-aging factors through plasma dilution or TPE mitigates age-associated decline and shows translational promise in neurodegenerative disease.[1]

Emerging Applications and Future Directions

A 2026 review by Liu et al. in the Journal of Advanced Research summarizes five blood-based anti-aging therapy methods — heterochronic parabiosis, TPE, platelet-rich plasma injection, extracellular vesicle transfusion, and platelet factor transfusion — and discusses their anti-aging effects, responsible components, and translational challenges.[12]

Rony et al. argue that TPE is underutilized in both preventative and precision medicine, and that next-generation TPE therapies will involve personalized plasma biomarker monitoring and modulation feedback, with synergistic plasma infusion therapies to mitigate age-associated disease and promote tissue rejuvenation.[3]

The Plasma Life Center Difference

At Plasma Life Center, we evaluate each patient with the utmost care and detail. We provide a personalized approach, and our experts are always available to answer your questions.

Ready for expert-led care? Start your journey with a consultation.